Path molecular Flashcards
MED12 mutation
leiomyoma and leiomyosarcoma
endometrial tp53 mutation
-type 2 EM Ca (serous)
PTEN mutation
-Endometrial hyperplasia –> Type 1 endometrial ca
-
MMR/mlh1 gene defect
type 1 EM Ca
HMGIC and HMGIY (ch12 and ch6)
leiomyoma
KRAS
- low grade serous tumors of the ovary
- mucinous tumors of the ovary
- endometrial hyperplasia: nonatypical –> atypical
KOH test
- vulvovaginal candidiasis
- Trichomonas whiff test
NAATs (amplified nucleic acid tests)
chlamydia trichomatis
HPV 6 and 11
(vulvar) condyloma acuminatum
HPV 16 and 18
- Vulvar-IN –> (vulvar) basaloid and warty carcinomas
- Vaginal-IN –>SCCa vagina
- Cervical Ca
PAS(Alcian blue stain) +, cytokeratin 7+, S100-
(vulva) Extramammary Paget Disease
p16 over expression bc of increased CD14.
(cervix) SIL (Squamous Intraepithelial Lesion)
Ki-67 overexpression is indicative of what activity and is the marker of what?
Indicates high mitotic activity (brown stain). Marker for SIL
uterine TP53
Type 2 uterine endometrial Ca
Normal function of PTEN
Inactivation of PI3K, stopping PI3K from enhancing estrogen receptors and increasing expression at gene targets, stopping overgrowth of estrogen dependent cells.
Increased PI3K/AKT results in?
increased estrogen receptor activation
PI3K, TP53, PTEN
Malignant mixed mullerian tumors (uterine endometrial)
JAZF1 and SUZ12 translocation/fusion(?)
Low grade uterine endometrial stromal sarcoma
HMGIC (12q14) and HMGIY (6p); MED12 mutation
leiomyoma
KRAS, BRAF, ERBB2
Low grade serous borderline epithelial ovarian tumor
TP53, BRCA1/2
High grade serous Ca (Epithelial)
KRAS (ovarian)
mucinous tumors of the ovary
serum marker CA-125
Monotors expected recurrence and progression of ovarian Ca
alpha feto protein
yolk sac ovarian tumor
B-hCG elevation
- Germ Cell Choriocarcinoma (malignant, fatal)
- Gestational Choriocarcinoma (malignant, curable)
- Complete/partial mole
inhibin - serum marker for… and function
- Marker for granulosa cell ovarian tumor
- Function: inhibits FSH
FOX 2 mutation
adult type granulosa cell ovarian tumor (sex cord stromal tumor)
50% of ____ have DICER1 mutation
Sertoli-Leydig Cell Tumor (ovarian)
sFlt1 and sENG
Angiogenic factors released from placenta as a result of hypoxia, involved in PREECLAMPSIA.
Function of sFlt1
Antagonizes VEGF - decreases maternal/placental angiogenesis in PREECLAMPSIA.
Function of sENG
Inhibits TGF-B, decreasing endothelial proliferation fo NO, resutling in systemic vasoconstriction, HTN, hypoperfusion in PREECLAMPSIA.
hPL
Placental Site Trophoblastic Tumor
